^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Two drug combinations are recommended by the panel as options for subsequent treatment of mCRC with HER2 amplifications: trastuzumab plus either pertuzumab or lapatinib.
Source:
Title:
Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.
Excerpt:
HER2 is amplified in 5% of WT exon 2 KRAS mCRC patients. The HERACLES trial met its primary endpoint with 8/23 objective responses in pts heavily pretreated with standard therapies, including EGFR-targeted agents, indicating that the dual anti HER2 therapy is effective...
DOI:
10.1200/jco.2015.33.15_suppl.3508
Trial ID:
Source:
Title:
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Excerpt:
At the time of data cutoff on Oct 15, 2015, with a median follow-up of 94 weeks (IQR 51-127), eight (30%, 95% CI 14-50) of 27 patients had achieved an objective response, with one patient (4%, 95% CI -3 to 11) achieving a complete response, and seven (26%, 95% CI 9-43) achieving partial responses; 12 (44%, 95% CI 25-63) patients had stable disease...The combination of trastuzumab and lapatinib is active and well tolerated in treatment-refractory patients with HER2-positive metastatic colorectal cancer.
DOI:
10.1016/S1470-2045(16)00150-9
Trial ID:
